Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 182, Issue 5, Pages 701-704Publisher
WILEY
DOI: 10.1111/bjh.15450
Keywords
myelofibrosis; anaemia; erythropoiesis stimulating agents; ruxolitinib; erythropoietin
Categories
Ask authors/readers for more resources
Erythropoiesis-stimulating agents (ESAs) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [DIPSS] intermediate-2/high risk; 525% transfusion-dependent). Anaemia response (AR) rate was 54% and 76% of patients responded at 5years. A further 15% displayed minor improvement in anaemia and 78% of patients reduced spleen size. Endogenous erythropoietin levels <125u/l correlated with a higher AR rate (63% vs. 20%, P=0008). No thrombotic events or other toxicities occurred. Overall survival was 62% at 4years, influenced by DIPSS and transfusion dependency. ESAs seem effective in improving anaemia in ruxruxolitinib-treated myelofibrosis patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available